Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

American Family Physician August 1, 2004 Mayfield & White	Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function New insulin preparations and a better understanding of insulin physiology provide more options for family physicians attempting to effectively tailor insulin therapy to the needs of individual patients.
Nursing Management January 2012 Lawrence et al.	Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support.
American Family Physician May 1, 2001 Beatriz Luna & Mark N. Feinglos	Oral Agents in the Management of Type 2 Diabetes Mellitus Currently, there are five distinct classes of hypoglycemic agents available, each class displaying unique pharmacologic properties...
Nurse Practitioner May 2011 Stacey A. Seggelke	Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes.
Managed Care May 2007 Rachel M. Renshaw	Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen.
American Family Physician June 15, 2006 Ezzo & Ambizas	Exenatide Injection (Byetta): Adjunctive Therapy for Glycemic Control Exenatide is an expensive, inconvenient drug that has no proven benefits over other drugs for diabetes management, including insulin.
American Family Physician September 15, 2006 Havas & Donner	Tight Control of Type 1 Diabetes: Recommendations for Patients Physicians play an important role in helping type 1 diabetes patients make essential lifestyle changes to help reduce the risk of microvascular and macrovascular complications.
Nursing November 2009 Christine Kessler	Glycemic control in the hospital: How tight should it be? Based on recent studies, the answer to that question remains controversial. This article will explore this issue and present current best practices for caring for a patient in the hospital who has diabetes or hyperglycemia.
American Family Physician January 1, 2003 Jennifer B. Marks	Perioperative Management of Diabetes Diabetic patients who require surgery present special challenges in perioperative management. Special attention must be paid to prevention and treatment of metabolic derangements.
Managed Care December 2003 Thomas Morrow	Can Amylin Analogue Lead To Better Diabetes Control? Maintaining tight glucose control is difficult to accomplish, but adding amylin to the mix may be the answer.
American Family Physician July 15, 2006 Jennifer D. Goldman-Levine	Insulin Detemir (Levemir) for Diabetes Mellitus Insulin detemir is suitable as basal insulin in a basal-bolus regimen. In limited research, it has been shown to cause slightly fewer episodes of minor hypoglycemia and no weight gain in patients with type 1 and 2 diabetes, which is a benefit that must be balanced against its higher price.
AskMen.com April 29, 2001 Joshua Levine	Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease...
American Family Physician April 15, 2004 Rao, Disraeli & Mcgregor	Impaired Glucose Tolerance and Impaired Fasting Glucose Impaired glucose tolerance and impaired fasting glucose form an intermediate stage in the natural history of diabetes mellitus.
Managed Care October 2005 Thomas Morrow	Incretin Hormones Poised For Better Control of Diabetes Enhanced management continues due to a greater understanding of the intricate glucose balance and the shortfalls of existing medications.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
American Family Physician November 1, 2003 Turok et al.	Management of Gestational Diabetes Mellitus Although the disorder affects approximately 2.5 percent of pregnant women and has been the subject of extensive research, its diagnosis and management continue to be debated.
Nursing September 2010 Margaret M. Bolton	Sounding the alarm about metabolic syndrome Any health problem that affects a third of American adults is sure to impact your nursing practice. Metabolic syndrome, a growing and commonly silent condition, poses a significant public health crisis.
American Family Physician December 15, 2000 Alan J. Garber	Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary...
American Family Physician October 15, 2003 Gavin et al.	Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels.
The Motley Fool June 28, 2010 Luke Timmerman	Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity.
American Family Physician March 15, 2001 Goutham Rao	Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value...
Pharmaceutical Executive March 1, 2013 Ben Comer	Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history.
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Nurse Practitioner February 2012 Jennifer M. Belavic	Annual drug update 2011 in review Many new medications were approved throughout 2011. This article will cover a variety of drugs that will be useful in nurse practitioner practice
AskMen.com Alex Santoso	What You Should Know About Diabetes Not many men understand what diabetes is, why it's very bad for them (it is one of the leading causes of impotence), what they can do to avoid getting it or how to treat it.
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
Pharmaceutical Executive October 1, 2005	Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions.
Nurse Practitioner February 2011 Jennifer M. Belavic	Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available.
The Motley Fool June 27, 2005 Stephen D. Simpson	Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well.
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
American Family Physician October 1, 2002 Konzem et al.	Controlling Hypertension in Patients with Diabetes Hypertension and diabetes mellitus are common diseases in the United States. Patients with diabetes have a much higher rate of hypertension than would be expected in the general population. Regardless of the antihypertensive agent used, a reduction in blood pressure helps to prevent diabetic complications.
American Family Physician October 15, 2000 Matthew Neff	Conference Highlights Lifestyle Modifications Can Prevent Onset of Type 2 Diabetes... Efficacy of Metformin Is Similar in Children and Adults... Glycemic Control Improves Quality of Life in Patients with Diabetes... Test Strip Proves Effective, Less Painful Alternative to Fingerstick...
American Family Physician May 1, 2001	Treatment Options for Type 2 Diabetes -- What's Available? What are the different steps in managing my diabetes? What are the different types of medicines used to treat type 2 diabetes and how do they work?
Nurse Practitioner October 2010 Hill & Appel	Diagnosing Diabetes with A1C: Implications and Considerations for Measurement and Surrogate Markers Now that the ADA has officially positioned the assay as a means of diagnosis and monitoring, it is another tool NPs must access properly when helping patients manage diabetes and treatment.
Managed Care April 2005	Diabetes Costs Rise, But so Does Adherence A typical health plan can expect endocrine and diabetes agents to amount to 6% to 8% of total utilization costs, with spending on these agents to increase between 11% and 15% 2005.
BusinessWeek December 22, 2003 Arlene Weintraub	Big Pharma Looks Beyond Insulin Researchers may be on the verge of major new treatments for diabetes and obesity.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
Nurse Practitioner July 2010 Kristine A. Scordo	Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease
The Motley Fool June 29, 2010 Brian Orelli	Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both.
The Motley Fool October 2, 2009 Brian Orelli	Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug.
Managed Care February 2004	Improving Oral Pharmacologic Treatment And Management of Type 2 Diabetes New oral treatment options and outcome measures may help patients with type 2 diabetes to achieve better results while reducing associated costs.
Pharmaceutical Executive December 1, 2008 Ron Feemster	The 2008 Pipeline Report We scrub industry's pipeline to find the drugs that everyone will be talking about in 2009 and beyond.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Diabetes: Agonists versus Inhibitors Diabetes is pharma's second-largest global market, worth close to $25 billion and growing by double digits annually, even in the developed world.
The Motley Fool August 21, 2007 Brian Orelli	Sweet Phase 3 Data Although diabetes drugs have come under fire lately, insulin maker Novo Nordisk is moving full steam ahead with its newest drug to help fight type 2 diabetes.
Pharmaceutical Executive May 1, 2009	The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?
The Motley Fool November 30, 2007 Brian Orelli	Analyzing Amylin Amylin Pharmaceuticals holds its R&D day to update investors on the marketing strategy of its two diabetes products, as well as the development of its pipeline.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
American Family Physician November 1, 2000	Diabetes: How Do I Know if I Have it? Diabetes is a disease that occurs when your body doesn't make enough of a hormone called insulin, or if your body doesn't use insulin the right way. If left untreated, it may result in blindness, heart attacks, strokes, kidney failure and amputations...
Managed Care November 2005 Thomas Morrow	This Nutritional Supplement Might be an Inexpensive Way to Improve Glycemic Control for the 18 Million Americans with Diabetes The review of the existing literature suggests that chromium picolinate with biotin offers people with diabetes hope for the future at a price that is less than what would be their copayment for a normal monthly generic drug.